Literature DB >> 17065628

In vitro killing of nosocomial pathogens by acid and acidified nitrite.

Agam Rao1, Robin L P Jump, Nicole J Pultz, Michael J Pultz, Curtis J Donskey.   

Abstract

Exposure to pH 1 or 2 buffers or acidic gastric contents resulted in the killing of vancomycin-resistant Enterococcus sp., Klebsiella pneumoniae, Staphylococcus aureus, and Candida glabrata but not Clostridium difficile spores. Nitrite enhanced killing under acidic conditions, but significant killing of C. difficile spores required nitrite concentrations above usual physiological levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065628      PMCID: PMC1635176          DOI: 10.1128/AAC.01506-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Overuse of acid-suppressive therapy in hospitalized patients.

Authors:  R J Nardino; R J Vender; P N Herbert
Journal:  Am J Gastroenterol       Date:  2000-11       Impact factor: 10.864

2.  Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice.

Authors:  Nicole J Pultz; Usha Stiefel; Mahmoud Ghannoum; Marion S Helfand; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

4.  Growth in cecal mucus facilitates colonization of the mouse intestinal tract by methicillin-resistant Staphylococcus aureus.

Authors:  Delores M Gries; Nicole J Pultz; Curtis J Donskey
Journal:  J Infect Dis       Date:  2005-09-28       Impact factor: 5.226

5.  Antimicrobial effect of acidified nitrite on gut pathogens: importance of dietary nitrate in host defense.

Authors:  R S Dykhuizen; R Frazer; C Duncan; C C Smith; M Golden; N Benjamin; C Leifert
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster.

Authors:  K H Wilson; J N Sheagren; R Freter
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

7.  A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program.

Authors:  C J Donskey; J R Schreiber; M R Jacobs; R Shekar; R A Salata; S Gordon; C C Whalen; F Smith; L B Rice
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

8.  Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study.

Authors:  Shelly A McNeil; Preeti N Malani; Carol E Chenoweth; Robert J Fontana; John C Magee; Jeffrey D Punch; Monica L Mackin; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2005-12-12       Impact factor: 9.079

9.  Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases.

Authors:  Claudia K Hoyen; Nicole J Pultz; David L Paterson; David C Aron; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

10.  Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital.

Authors:  R Ben-Ami; M J Schwaber; S Navon-Venezia; D Schwartz; M Giladi; I Chmelnitsky; A Leavitt; Y Carmeli
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

View more
  26 in total

1.  Suppression of gastric acid production by proton pump inhibitor treatment facilitates colonization of the large intestine by vancomycin-resistant Enterococcus spp. and Klebsiella pneumoniae in clindamycin-treated mice.

Authors:  Usha Stiefel; Agam Rao; Michael J Pultz; Robin L P Jump; David C Aron; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  The impact of proton pump inhibitors on the human gastrointestinal microbiome.

Authors:  Daniel E Freedberg; Benjamin Lebwohl; Julian A Abrams
Journal:  Clin Lab Med       Date:  2014-09-24       Impact factor: 1.935

Review 3.  The Intersection Between Colonization Resistance, Antimicrobial Stewardship, and Clostridium difficile.

Authors:  Rossana Rosa; Curtis J Donskey; L Silvia Munoz-Price
Journal:  Curr Infect Dis Rep       Date:  2018-06-07       Impact factor: 3.725

Review 4.  Clostridium difficile infection: new insights into management.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

Review 5.  Nitrite reduction by molybdoenzymes: a new class of nitric oxide-forming nitrite reductases.

Authors:  Luisa B Maia; José J G Moura
Journal:  J Biol Inorg Chem       Date:  2015-01-15       Impact factor: 3.358

6.  Regularized S-Map Reveals Varying Bacterial Interactions.

Authors:  Zhong Yu; Zhihao Gan; Hao Huang; Yuelan Zhu; Fangang Meng
Journal:  Appl Environ Microbiol       Date:  2020-10-01       Impact factor: 4.792

7.  Clostridium difficile in the Long-Term Care Facility: Prevention and Management.

Authors:  Robin L P Jump; Curtis J Donskey
Journal:  Curr Geriatr Rep       Date:  2015-03

Review 8.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

9.  Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection.

Authors:  Michelle M Nerandzic; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

Review 10.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.